DexCom (NASDAQ:DXCM) Releases Quarterly Earnings Results

DexCom (NASDAQ:DXCM) released its quarterly earnings results on Thursday. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.09, FiscalAI reports. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period last year, the company earned $0.48 EPS.

Here are the key takeaways from DexCom’s conference call:

• Positive Sentiment: Dexcom reported Q2 revenue of $1.31 billion, up 13% year over year, with international revenue rising 19%. Management raised full-year revenue guidance to $5.18–$5.25 billion and increased gross and operating margin outlooks.
• Positive Sentiment: The CONNECT trial showed a 1.6% A1C improvement among non-insulin type 2 diabetes patients, with 97% median CGM utilization. Dexcom believes the results could support broader commercial and Medicare reimbursement, including a potential CMS decision by year-end and coverage beginning in mid-2027.
• Positive Sentiment: G7 15-day adoption is tracking to plan, with nearly 50% of the U.S. customer base expected to convert by year-end. The product is now integrated with Tandem systems, has received Canadian regulatory clearance, and is contributing to stronger customer satisfaction and future margin expansion.
• Positive Sentiment: Strong execution drove non-GAAP gross margin to 64.1%, adjusted EBITDA margin to 32.2%, and more than $600 million of free cash flow in the first half. Dexcom repurchased approximately $600 million of stock in Q2 under its $1 billion 2026 authorization and completed its acquisition of Nutrisense to add personalized nutrition insights.
• Neutral Sentiment: Growth initiatives carry some near-term cost and execution considerations, including hiring and startup expenses for the Ireland manufacturing facility and approximately $15 million of second-half international revenue pressure from foreign exchange. Management expects gross margin to dip as Ireland production begins before leveraging over time.

DexCom Stock Down 0.8%

NASDAQ:DXCM traded down $0.60 during mid-day trading on Thursday, hitting $74.54. The company had a trading volume of 5,620,753 shares, compared to its average volume of 5,218,646. The business has a fifty day simple moving average of $72.86 and a 200-day simple moving average of $69.05. The firm has a market capitalization of $28.76 billion, a price-to-earnings ratio of 31.85, a PEG ratio of 1.23 and a beta of 1.45. DexCom has a 1 year low of $54.11 and a 1 year high of $87.00. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 analyst consensus, while revenue reached $1.31 billion, ahead of estimates of $1.29 billion. Dexcom Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year revenue forecast raised: Management now expects fiscal 2026 revenue of approximately $5.2 billion to $5.3 billion, compared with consensus around $5.2 billion. The higher outlook reflects strong and sustained demand for continuous glucose monitors. Dexcom raises annual revenue forecast on strong demand for glucose monitors
• Positive Sentiment: Analyst support remains favorable: UBS reaffirmed its “buy” rating and set a $96 price target, implying meaningful upside from recent trading levels. The broader analyst consensus remains “Moderate Buy,” with an average target of $85.40.
• Neutral Sentiment: Valuation and expectations remain important: DXCM trades at roughly 32 times earnings, so continued appreciation may depend on the company sustaining revenue growth and converting strong demand into profit expansion.
• Negative Sentiment: Insider selling may temper sentiment: Former CEO Kevin Sayer sold 26,756 shares worth about $2.04 million. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, reducing its significance as a direct signal about near-term business prospects. DexCom insider transaction filing

Insider Buying and Selling

In other DexCom news, EVP Jon Coleman sold 4,911 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $74.13, for a total value of $364,052.43. Following the transaction, the executive vice president owned 95,450 shares in the company, valued at $7,075,708.50. The trade was a 4.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the transaction, the insider directly owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. The trade was a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 98,506 shares of company stock valued at $7,205,258. 0.28% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. DV Equities LLC purchased a new position in DexCom in the fourth quarter valued at about $36,000. Aster Capital Management DIFC Ltd acquired a new position in shares of DexCom in the 4th quarter valued at approximately $63,000. Quarry LP purchased a new position in shares of DexCom during the 3rd quarter valued at approximately $72,000. MUFG Securities EMEA plc acquired a new stake in DexCom in the second quarter valued at $100,000. Finally, Summit Securities Group LLC boosted its stake in DexCom by 817.2% during the 4th quarter. Summit Securities Group LLC now owns 1,174 shares of the medical device company’s stock valued at $78,000 after acquiring an additional 1,046 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on DXCM shares. Robert W. Baird set a $80.00 target price on shares of DexCom in a research report on Friday, May 1st. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Deutsche Bank Aktiengesellschaft began coverage on DexCom in a report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price objective on the stock. Truist Financial lifted their price objective on DexCom from $80.00 to $87.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, Bank of America dropped their target price on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $85.40.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.